



Immunohistochemistry and Special Stain Requisition

Client Information		Patient Informati	on			
Required Information Account #: Account Name:		Last Name:			🗆 Male 🔲 Female	
Street Address:					cct #:	
City, ST, ZIP:					rd #:	
Phone: Fax:	By completing this section,		tained informed consent fro			
Additional Reporting Fax:	services described herein.					
Ordering Physician: NPI #:		Specimen Inform	ation			
(please print: Last, First): Treating Oncologist/Physician: NPI #: _		-		Block ID:		
(please print: Last, First): The undersigned certifies that he/she is licensed to order the test(s) listed below and that such test(s) are		Fixative/Preservative:				
medically necessary for the care/treatment of this patient.		Collection Date: mm / dd / yyyy Collection Time:				
Authorized Signature: Date:			Retrieved Date: mm			
Billing Information			Body Site:			
Required: Please include face sheet and front/back of card for both primary and	☐ Primary ☐ Metastasi		nary:			
Patient Status (Must Choose 1): ☐ Hospital Patient (in) ☐ Hospital Patient (out)	☐ FNA cell block: Stained (type of stain)					
Bill to: ☐ Client Bill ☐ Insurance ☐ Medicare ☐ Medicaid		☐ Smears: Air Dried Fixed Stained (type of stain) ☐ Slides # Unstained Stained ☐ H&E				
 □ Split Billing - Client (TC) and Insurance (PC) □ OP Molecular to MCR □ Bill charges to other Hospital/Facility: 						
Prior Authorization # See NeoGenomics.com/bil	□ Paraffin Block(s) #: □ Perform IHC testing on all blocks, unless otherwise noted. For all other testing, specify which block to use for each if sending multiple blocks. See back for details.					
	Predictive Marker Fixation (CAP/ASCO Requirement):					
Clinical Information	*Indicated markers/panels/profiles require fixation information Cold ischemic duration (mins): □ ≤ 1 hour □ Unknown					
Required: Please attach patient's pathology report (required), clinical history, and	Fixative: 10% NBF	☐ Other:		■ Unknown		
ICD 10 (Diagnosis) Code/Narrative (Required):	Fixation duration (hours):			■ Unknown		
Reason for Referral: In Remission Monitoring		G - Global G-IA - Global w	ith Image Analysis T - Tec	:h-Only/Stain-Only T-IA - Te	ch-Only with Image Analysis	
		T-SQnt - Tech-Only with Sen	ni-Quantitative interpretatio	n by client		
Consultation - A NeoGenomics pathologist will select medically necessary tests with	Tech-Only Qualitative	IHC/ISH/Special Stains			interpretation is available.	
any exception noted below by the client to provide comprehensive analysis and professional interpretation for the materials submitted. Performed on FFPE only.	☐ AAT ☐ CD15	- 0.404.45	☐ LMO2	ck here to add PAX8	Special Stains	
☐ Surgical Pathology Consult (FFPE only) ☐ Add NeoTYPE* Profile if indicated Differential Diagnosis:	ACTH CD19	D240 □ D240	■ Lysozyme	□ PD1	G T	
•	☐ AFP ☐ CD20 ☐ ALK-1 (Heme) ☐ CD21		■ MAL■ Mammaglobin	□ PD1 (non-heme)□ Perforin	N/A Alcian Blue	
Image Analysis/Semi-Quantitative IHC G-IA T-IA T-SQnt G-IA T-IA T-SQnt	☐ Annexin A1 ☐ CD22	DOG1	☐ MDM2 °	☐ PgR	☐ ☐ Calcium Stain N/A ☐ Colloidal Iron	
□ □ □ AR □ □ □ MLH1	☐ AR ☐ CD23 ☐ Arginase 1 ☐ CD2 5		☐ Melan A (Mart1) ☐ Melan A/Ki67	☐ PIT1 ☐ PLAP	N/A Congo Red	
□ □ □ ER [‡] □ □ □ MSH2 □ □ □ HER2 Breast** [‡] □ □ □ MSH6	☐ ATRX ☐ CD30	o‡ □ E-Cadherin	■ Melanoma Micromet	ts 🗖 PRAME	N/A Copper Stain N/A Elastic Stain	
□ □ □ Ki67 [‡] □ □ □ PMS2	□ B72.3 □ CD31 □ BAP1 □ CD33		(HMB45 with Melan A/Mart1)	□ Prolactin□ Prostate Triple Stain	N/A Fontana Masson	
PgR	BCL1/Cvclin D1 CD34	I □ ERG	■ Mesothelin	□ PSA	N/A ☐ Iron N/A ☐ Mucicarmine	
**For global HER2 IHC with result 2+, NeoGenomics will add global HER2 FISH unless marked here: □ Do not reflex 2+	BCL1/Cyclin D1 CD35 (carcinoma) CD38		Mismatch Repair (MMR) MLH1	D PSMA	N/A □ PAS N/A □ PASD	
Semi-Quantitative	BCL2 CD42	2b ☐ Fascin	☐ MSH2	□ PTH	PASD Periodic Acid Schiff	
G T G T	BCL2		☐ MSH6 ☐ PMS2	□ RCC1 □ S100	with Digestion (PASD+PAS)	
□□ BRCA1 □□ pAKT □□ PD-L1 28-8 □□ cMET □□ PD-L1 22C3 FDA (OPDIVO") for	BCL6 CD45	(LCA) G FSH	☐ All 4 Stains ☐ MITF	□ S100p	N/A Reticulin	
□□ EGFR for NSCLC* [‡] Gastric/ GF.J/FAC* [‡]	BerEP4 CD56	□ CATA2	MOC31	☐ SALL4 ☐ SATB2	N/A ☐ Trichrome N/A ☐ Wright Giemsa	
□□ ERCC1	☐ Beta Catenin ☐ CD61	1 GCDFP15	☐ MPO ☐ MSA	☐ SF1 ☐ SMA	-	
☐☐ HER2 Gastric/GEA*** ☐☐ ESCC (Esophageal) ☐☐ PD-L1 LDT**	BRAF V600E [‡] CD68	ı́ □ GFAP	■ MUC1	□ SMMHC	In-Situ Hybridization G T	
☐ HER2 (Other)*** ☐ Gastric/GEA ☐ pHistone H3 (PHH3) ☐ Breast Scoring (Default) ☐ HNSCC (Head & Neck) ☐ PTEN	☐ Breast ☐ CD79	ga □ GH	☐ MUC2 ☐ MUC4	☐ Smoothelin ☐ SSTR2	N/A ☐ Albumin RNA ISH	
or □□ TNBC (Breast) □□ Retinoblastoma	(CK5+p63+CK ☐ CD10	Synthetase	■ MUC5	(Somatostatin	□ □ CMV ISH	
Gastric Scoring PD-L1 SP142 FDA (TECENTRIQ*)** Protein (RB) Ki67 NET	8/18)		☐ MUC6 ☐ MUM1	Receptor, Type 2) SOX2	☐ ☐ EBER ISH☐ N/A HPV RNA ISH	
□□ n53 □□ PD-I 1.28-8 FDA □□ Thymidylate	(SMARCA4) (Mel	lanoma) 🗆 Glypican-3	■ MyoD1	■ S0X10	Panel (Complete)	
for NSCLC** Synthase *Ordering Pathologist listed has received the required competency training to	□ CA19.9 □ CD12 □ CA125 □ CD13		☐ Myogenin☐ Napsin A	□ SOX11 □ STAT6	N/A HPV RNA ISH 16/18 High Risk	
perform the professional interpretation for this test.	CD16	HBME1	☐ NeuN☐ NF (Neurofilament)	☐ Synaptophysin☐ TCL1	■ N/A HPV RNA ISH	
Qualitative	CDX2	7 ☐ HepPar1	□ NKX2.2	☐ TCR BetaF1	High Risk Cocktail ■ N/A HPV RNA ISH	
G T	CDX2	2/CK7 HGAL	□ NKX3.1 □ NS E	☐ TCR Delta ☐ TdT	Low Risk Cocktail	
(lung, FDA) [‡] (global only) [*] □ N/A Pan-TRK [‡]	Carbonic Doub	(Mono) HPL	■ NUT	☐ TFE3	N/A Kappa/Lambda ISH	
$N/A \square$ Amyloid A \square \square BRAF V600E \square \square p16 N/A \square Amyloid P \square (non-heme)* \square \square ROS1*	Anhydrase IX CEA	(Poly)	□ OCT2) □ OCT4	☐ Thrombomodulin (TM)☐ Thyroglobulin (TGB)	Other:	
*Congo Red slide must accompany sample OR order Consult	Carcinoma CK 5/	/6 □ IDH1 [‡]	☐ Olig2	☐ TIÁ1	Out01	
Micromets Clevels with CK			□ p40 □ p57	☐ TLE1 ☐ TRAcP		
Infectious Disease	AE1/AE3) CK 17	7 □ lgG	□ p63	□ Tryptase		
G T G T G T □ □ Adenovirus □ □ Hep B Core □ □ Pneumocystis	□ CD1a □ CK 18 □ CD2 □ CK 19	8 □ lgG4 9 □ lgM	□ p63 (heme)□ p120 Catenin	□ TSH □ TTF1		
□ □ △FB Antigen Carinii (Jiroveci)	CK 20	0 Inhibin	□ p501S	□ Tyrosinase		
☐ ☐ CMV (IHC) ☐ Hep B Surface ☐ ☐ Spirochete	□ CD4 □ CK HI □ CD5 □ CK HI	na/a4oBE1a\□ INSM1	☐ p504S ☐ Pan-Cytokeratin	□ Uroplakin II□ Uroplakin III		
N/A LEBV (LMP1)	H CD7	IMW/LMW 📙 Kappa/Lambda IHI	🗀 Pan-Ćytokeratin	☐ Villin		
☐ ☐ GMS ☐ ☐ Parvovirus ☐ ☐ Varicella Zoster	I□ CD10 □ ck no	ole Stain	(sentinel-node) ☐ Parafibromin	☐ Vimentin ☐ WT1		
☐ Gram Stain ☐ Periodic Acid Virus (VZV) ☐ ☐ H Pylori Schiff for Fungus (PASF)	☐ cMy	c LEF1	□ PAX2 □ PAX5			
H. Pylori Schill for Fungus (PASF)	Colla	agen IV 🔲 LH	- 1700			

Specimen Requirements

Refrigerate specimen if not shipping immediately and use cool pack during transport. Please call Client Services team with any questions regarding specimen requirements or shipping instructions at 866.776.5907 option 3. Please refer to the website for specific details on each specimen.

Additional Billing Information

Any organization referring specimens for testing services pursuant to this Requisition Form ("Client") expressly agrees to the following terms and conditions.

- 1. Binding Service Order. This Requisition Form is a contractually binding order for the services ordered hereunder ("Services") and Client agrees that it is financially responsible for all tests billable to Client hereunder.
- 2. Third Party Billing by NeoGenomics and Right to Bill Client. Client agrees to accurately indicate on the front of the Requisition Form that either Client should be billed (e.g., Client receives reimbursement pursuant to a non-fee-for-service basis, including, but not limited to, a capitated, diagnostic related group ("DRG"), per diem, all-inclusive, or other such bundled or consolidated billing arrangement) or NeoGenomics should bill the applicable federal, state or commercial health insurer or other third party payer (collectively, "Payers") for all Services ordered pursuant to this Requisition Form. For all such Services billable to Payers, Client agrees to provide all billing information necessary for NeoGenomics to bill such payer. In the event NeoGenomics: (i) does not receive the billing information required for it to bill any Payers within ten days of the date that any Services are reported by NeoGenomics; (ii) the Services were performed for patients who have no Payer coverage arrangements; or (iii) the Payer identified by Client denies financial responsibility for the Services and indicates that Client is financially responsible, NeoGenomics shall have the right to bill such Services to Client.

Additional Specimen Information

If submitting multiple blocks, clients must indicate either "Choose best block (global molecular/NGS testing only)", "Perform IHC testing on all blocks", or assign the selection of blocks to individual tests. If multiple blocks are sent without a selection, they will be held until clarification is provided. Please call Client Services team with any questions regarding specimen information.

Test Descriptions

Please see complete test descriptions and all available tests at our website, www.neogenomics.com/test-menu.

Test Notations

Specimen Usage

NeoGenomics makes every effort to preserve and not exhaust tissue, but in small and thin specimens, there is a possibility of exhausting the specimen in order to ensure adequate material and reliable results.